Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

PURPOSE: Telisotuzumab vedotin (Teliso-V) is an anti–c-Met–directed antibody–drug conjugate. Here, we present safety and efficacy data from a phase I/Ib study of Teliso-V monotherapy evaluated in once every 2 weeks/once every 3 weeks schedules in patients with non–small cell lung cancer (NSCLC). PAT...

Descripción completa

Detalles Bibliográficos
Autores principales: Camidge, D. Ross, Morgensztern, Daniel, Heist, Rebecca S., Barve, Minal, Vokes, Everett, Goldman, Jonathan W., Hong, David S., Bauer, Todd M., Strickler, John H., Angevin, Eric, Motwani, Monica, Parikh, Apurvasena, Sun, Zhaowen, Bach, Bruce Allen, Wu, Jun, Komarnitsky, Philip B., Kelly, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401525/
https://www.ncbi.nlm.nih.gov/pubmed/34426443
http://dx.doi.org/10.1158/1078-0432.CCR-21-0765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401525/
https://www.ncbi.nlm.nih.gov/pubmed/34426443
http://dx.doi.org/10.1158/1078-0432.CCR-21-0765

Ejemplares similares